Breaking News Instant updates and real-time market news.

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59

Xenon to provide updates on partnered epilepsy programs

Xenon Pharmaceuticals (XENE) announced that it will provide updates on its partnered epilepsy programs at the American Epilepsy Society Annual Meeting. Dr. Simon Pimstone, Xenon's CEO, said, "There are a number of presentations at the AES meeting related to our recently announced license and collaboration with Neurocrine Biosciences. Our presentations provide details on the clinical stage XEN901 epilepsy program and other pre-clinical licensed Nav1.6 and dual Nav1.2/1.6 programs. In addition to the scientific poster sessions at AES, we will be presenting information on both our partnered and proprietary programs at the BioMarin scientific exhibit on Sunday." A poster presentation entitled, "A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of XEN901, a Novel, Selective Nav1.6 Sodium Channel Inhibitor for the Treatment of SCN8A-Related Epilepsy" will be presented as Poster #15 in the BioMarin (BMRN) exhibit. In a poster entitled, "XEN393, A Novel Selective Dual Inhibitor of Nav1.2/Nav1.6 Channels Prevents Electrically-Induced Seizures in Mice and Rats," data are presented that show dual Nav1.2/1.6 inhibitors may provide a novel, mechanistically differentiated profile distinct from all marketed non isoform selective sodium channel blockers, Xenon added.

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

  • 07

    Dec

XENE Xenon Pharmaceuticals
$13.92

0.03 (0.22%)

03/29/19
STFL
03/29/19
INITIATION
Target $21
STFL
Buy
Xenon Pharmaceuticals price target raised, coverage transferred at Stifel
Stifel analyst Paul Matteis took over coverage of Xenon Pharmaceuticals from Stephen Willey with a maintained Buy rating and raised price target of $21, up from the prior target of $18. Matteis believes just one of Xenon's three lead epilepsy assets needs to succeed to drive the stock meaningfully higher from current levels, he tells investors.
09/20/19
GUGG
09/20/19
INITIATION
Target $25
GUGG
Buy
Xenon Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Xenon Pharmaceuticals with a Buy and $25 price target.
09/20/19
GUGG
09/20/19
INITIATION
Target $25
GUGG
Buy
Guggenheim starts Xenon Pharmaceuticals at Buy, sees good odds for lead asset
As previously reported, Guggenheim analyst Yatin Suneja initiated Xenon Pharmaceuticals with a Buy rating and $25 price target. The analyst likes the company's focus on developing precision therapies for rare genetic epileptic conditions and sees its lead asset, XEN496, having "a relatively high probability of success." Meanwhile, pipeline product XEN1101 offers an attractive profile in adult focal epilepsy and XEN901 has the potential to offer better efficacy than current sodium channel blockers, said Suneja.
BMRN BioMarin
$79.90

-0.18 (-0.22%)

11/27/19
LEHM
11/27/19
UPGRADE
Target $98
LEHM
Overweight
BioMarin upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Gena Wang upgraded BioMarin to Overweight from Equal Weight with a $98 price target.
11/27/19
LEHM
11/27/19
UPGRADE
Target $98
LEHM
Overweight
Barclays upgrades BioMarin to Overweight ahead of achondroplasia data
Barclays analyst Gena Wang upgraded BioMarin Pharmaceutical to Overweight from Equal Weight with a price target of $98, up from $86. The analyst sees a favorable risk/reward into the Phase 3 data readout for vosoritide, which she expects will be positive. Vosoritide's Phase 3 trial for treating achondroplasia is "well powered to allow for statistical significance," Wang tells investors in a research note. Further, the analyst believes BioMarin shares reflect little value for its hemophilia A gene therapy, ValRox.
11/27/19
11/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) upgraded to Strong Buy from Outperform at Raymond James with analyst Matthew McClintock saying he has become more comfortable with the company's risk/return profile, particularly regarding execution risk and valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from In Line at Evercore ISI and to Overweight from Equal Weight at Barclays. 3. Masonite (DOOR) upgraded to Buy from Neutral at Northcoast. 4. BioMarin (BMRN) upgraded to Overweight from Equal Weight at Barclays with analyst Gena Wang saying she sees a favorable risk/reward into the Phase 3 data readout for vosoritide, which she expects will be positive. 5. Envestnet (ENV) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/03/19
SBSH
12/03/19
UPGRADE
Target $60
SBSH
Neutral
Audentes Therapeutics upgraded to Neutral from Sell at Citi
Citi analyst Mohit Bansal upgraded Audentes Therapeutics (BOLD) to Neutral from Sell with a price target of $60, up from $30, after the company agreed to be acquired by Astellas for $60 per share. The analyst says he "clearly underestimated big pharma's appetite for gene therapy." He thinks the premium paid by Astellas is based on value of technology and Audentes's preclinical pipeline. Gene therapy should continue to be a target, and BioMarin (BMRN) "could fit the bill," Bansal tells investors in a research note. The analyst expects gene therapy stocks to trade up on the Audentes deal.

TODAY'S FREE FLY STORIES

WMT

Walmart

$115.30

-0.59 (-0.51%)

11:28
01/17/20
01/17
11:28
01/17/20
11:28
Periodicals
Walmart chief merchant Steve Bratspies to depart, WSJ reports »

Walmart chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

NFLX

Netflix

$339.15

0.48 (0.14%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Hot Stocks
Netflix opens new Paris office, boosts investment in France »

Netflix announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

11:25
01/17/20
01/17
11:25
01/17/20
11:25
General news
Philly Fed's Harker said the economy is looking "pretty good," »

Philly Fed's Harker…

AMED

Amedisys

$180.60

-0.59 (-0.33%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Conference/Events
Amedisys participates in a conference call with Benchmark »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

IBM

IBM

$137.15

-0.85 (-0.62%)

, PINS

Pinterest

$23.11

0.15 (0.65%)

11:24
01/17/20
01/17
11:24
01/17/20
11:24
On The Fly
IBM downgrade, Pinterest upgrade among today's top analyst calls »

Check out today's top…

IBM

IBM

$137.15

-0.85 (-0.62%)

PINS

Pinterest

$23.11

0.15 (0.65%)

EBAY

eBay

$35.69

-0.22 (-0.61%)

TWTR

Twitter

$34.11

-0.08 (-0.23%)

SNAP

Snap

$19.10

0.85 (4.66%)

QCOM

Qualcomm

$95.08

3.305 (3.60%)

WDC

Western Digital

$68.69

0.07 (0.10%)

LUV

Southwest

$55.31

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

NCLH

Norwegian Cruise Line

$59.43

0.84 (1.43%)

11:21
01/17/20
01/17
11:21
01/17/20
11:21
Periodicals
Breaking Periodicals news story on Norwegian Cruise Line »

Hedgeye names Norwegian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/17/20
01/17
11:17
01/17/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/17/20
01/17
11:16
01/17/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$7.45

-0.49 (-6.17%)

11:15
01/17/20
01/17
11:15
01/17/20
11:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

VWAGY

Volkswagen

$0.00

(0.00%)

10:28
01/17/20
01/17
10:28
01/17/20
10:28
Periodicals
VW set to acquire 20% stake in Chinese battery maker Guoxuan, Reuters reports »

Volkswagen is poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.